Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC.

被引：0
|
作者：
Jacobs, Ryan [1 ]
Fong, Jason [1 ]
Moravec, David [1 ]
Botting, Greg [1 ]
Bomgarden, Ryan [2 ]
Rogers, John [2 ]
Viner, Rosa [3 ]
Blank, Michael [3 ]
Puri, Neelu [1 ]
机构：
[1] Univ Illinois, Rockford, IL USA
[2] Thermo Fisher Sci, Rockford, IL USA
[3] Thermo Fisher Sci, San Jose, CA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-5653
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5653
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Helena Linardou
    Issa J. Dahabreh
    Dimitrios Bafaloukos
    Paris Kosmidis
    Samuel Murray
    Nature Reviews Clinical Oncology, 2009, 6 : 352 - 366
  • [42] Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Linardou, Helena
    Dahabreh, Issa J.
    Bafaloukos, Dimitrios
    Kosmidis, Paris
    Murray, Samuel
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (06) : 352 - 366
  • [43] EGFR, C-Met and Axl Expressions as Predictive Factors of Tyrosine Kinase Inhibitor Response in EGFR Mutated Lung Adenocarcinomas
    Lantuejoul, Sylvie
    Gervasoni, Julie
    McLeer, Anne
    Fina, Frederic
    Sakhri, Linda
    de Fraipont, Florence
    Nagy-Mignotte, Helene
    Moro-Sibilot, Denis
    Brambilla, Elisabeth
    LABORATORY INVESTIGATION, 2015, 95 : 481A - 481A
  • [44] EGFR, C-Met and Axl Expressions as Predictive Factors of Tyrosine Kinase Inhibitor Response in EGFR Mutated Lung Adenocarcinomas
    Lantuejoul, Sylvie
    Gervasoni, Julie
    McLeer, Anne
    Fina, Frederic
    Sakhri, Linda
    de Fraipont, Florence
    Nagy-Mignotte, Helene
    Moro-Sibilot, Denis
    Brambilla, Elisabeth
    MODERN PATHOLOGY, 2015, 28 : 481A - 481A
  • [45] Novel quinazoline-based dual EGFR/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity
    Zhang, Han
    Gan, Wenhui
    Fan, Dang
    Zheng, Pengwu
    Lv, Qiaoli
    Pan, Qingshan
    Zhu, Wufu
    BIOORGANIC CHEMISTRY, 2024, 142
  • [46] DESIGN, SYNTHESIS AND ACTIVITY OF NOVEL QUINAZOLINES DERIVATIVES AS DUAL EGFR/C-MET INHIBITORS
    Wang, C. L.
    Zhang, B. L.
    Han, J. Q.
    Xiong, Y. J.
    Guo, Y. P.
    Xu, S.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 32 - 33
  • [47] EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
    Dong, Rui-Fang
    Zhu, Miao-Lin
    Liu, Ming-Ming
    Xu, Yi-Ting
    Yuan, Liu-Liu
    Bian, Jing
    Xia, Yuan-Zheng
    Kong, Ling-Yi
    PHARMACOLOGICAL RESEARCH, 2021, 167
  • [48] A c-Met receptor tyrosine kinase inhibitor offers increased radiosensitization in NSCLC after pretreatment with Erlotinib
    Welsh, James
    Ellsworth, Ron
    Mahadevan, Daruka
    Bearss, David
    Komaki, Ritsuko
    Stea, Baldassarre
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S957 - S958
  • [49] Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma
    Akhavan-Sigari, R.
    Abili, M.
    Gaab, M. R.
    Rohde, V.
    Zafar, N.
    Emami, P.
    Ostertag, H.
    NEUROSURGICAL REVIEW, 2015, 38 (01) : 89 - 98
  • [50] Targeting the Golgi apparatus to overcome acquired resistance of NSCLC cells to EGFR tyrosine kinase inhibitors
    Ohashi, Yoshimi
    Okamura, Mutsumi
    Katayama, Ryohei
    Akatsuka, Akinobu
    Fujita, Naoya
    Shiina, Isamu
    Yoshimatsu, Kentaro
    Yamori, Takao
    Dan, Shingo
    CANCER SCIENCE, 2018, 109 : 563 - 563
12345